Top Page
Envoy Medical
(NASDAQ:COCH)
Envoy Medical (COCH) vs. SPDR S&P 500 ETF (SPY)
Envoy Medical Business Overview & Revenue Model
Envoy Medical Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 208.00K | 225.00K | 316.00K | 237.00K | 310.00K |
| Gross Profit | -612.00K | -517.00K | -473.00K | -261.00K | -459.00K |
| EBITDA | -19.54M | -19.81M | -29.79M | -8.63M | -6.80M |
| Net Income | -21.79M | -20.80M | -29.92M | -15.92M | -8.68M |
Balance Sheet | |||||
| Total Assets | 8.18M | 11.54M | 8.27M | 2.56M | 2.62M |
| Cash, Cash Equivalents and Short-Term Investments | 3.56M | 5.48M | 4.22M | 183.00K | 1.12M |
| Total Debt | 946.00K | 19.66M | 562.00K | 34.53M | 23.48M |
| Total Liabilities | 15.71M | 30.38M | 10.05M | 38.75M | 47.58M |
| Stockholders Equity | -7.53M | -18.84M | -1.78M | -36.20M | -44.96M |
Cash Flow | |||||
| Free Cash Flow | -16.38M | -18.93M | -17.24M | -9.02M | -7.06M |
| Operating Cash Flow | -16.90M | -17.95M | -17.09M | -8.80M | -6.94M |
| Investing Cash Flow | 527.00K | -980.00K | -153.00K | -218.00K | -125.00K |
| Financing Cash Flow | 15.51M | 20.20M | 21.28M | 8.09M | 8.06M |
Envoy Medical Technical Analysis
Envoy Medical Risk Analysis
Envoy Medical Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $142.09M | -6.53 | ― | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $45.36M | -11.38 | -91.34% | ― | 250.35% | 83.06% | |
48 Neutral | $20.45M | -1.12 | -335.47% | ― | 18.76% | 60.09% | |
46 Neutral | $19.86M | -0.18 | -210.36% | ― | -70.54% | 70.03% | |
43 Neutral | $20.08M | -0.52 | ― | ― | -25.18% | -9.71% |
Envoy Medical Corporate Events
On December 18, 2025, Envoy Medical, Inc. amended the terms of 1,125,499 previously issued Shortfall Warrants held by several Meteora-affiliated investment funds, extending their expiration date by one year from December 31, 2025, to December 31, 2026. The warrants, whose exercise price is set weekly based on a volume-weighted average price formula subject to a $1.50 per share minimum, had their underlying Class A common stock issuance and resale, as well as the resale of the Shortfall Warrants themselves, registered under a shelf registration statement that was declared effective by the SEC on August 12, 2025, helping preserve potential future capital-raising flexibility for Envoy Medical and liquidity options for the Meteora investors.
The most recent analyst rating on (COCH) stock is a Hold with a $0.67 price target. To see the full list of analyst forecasts on Envoy Medical stock, see the COCH Stock Forecast page.
Envoy Medical has released an updated investor presentation detailing its strategic plans and the development of its Acclaim CI, a fully-implanted cochlear implant. The company anticipates completing pivotal trial enrollment by Q1 2026 and expects FDA approval by the end of 2027. With an estimated 2.8 million potential candidates in the U.S., Envoy Medical aims to capture a significant portion of the untapped cochlear implant market, offering a differentiated solution with no visible hardware and enhanced usability.
The most recent analyst rating on (COCH) stock is a Hold with a $0.83 price target. To see the full list of analyst forecasts on Envoy Medical stock, see the COCH Stock Forecast page.
On November 26, 2025, Envoy Medical, Inc. held a Special Meeting of Stockholders where stockholders approved the issuance of warrants to purchase shares of Class A Common Stock to comply with Nasdaq Listing Rule 5635(d). Additionally, an administrative proposal allowing adjournments of the meeting was approved but not utilized.
The most recent analyst rating on (COCH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Envoy Medical stock, see the COCH Stock Forecast page.
On November 19, 2025, Envoy Medical, Inc. received a notice from Nasdaq indicating that its Class A Common Stock failed to meet the $1.00 minimum bid price requirement for continued listing. The company has until May 18, 2026, to regain compliance, with options including a reverse stock split if necessary. Failure to comply may result in delisting, though the company plans to monitor stock prices and consider actions to meet the requirements.
The most recent analyst rating on (COCH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Envoy Medical stock, see the COCH Stock Forecast page.
On October 27, 2025, Envoy Medical announced that the Nasdaq Hearings Panel granted the company an extension for continued listing on the Nasdaq Stock Market. This decision was influenced by Envoy Medical’s recent equity capital raises, debt extinguishment, and the FDA’s approval to advance to the final stage of the Acclaim® cochlear implant clinical trial. The company has until February 23, 2026, to comply fully with Nasdaq Listing Rule 5550(b)(2), during which it will continue to update Nasdaq and the public on its compliance progress.
The most recent analyst rating on (COCH) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Envoy Medical stock, see the COCH Stock Forecast page.
On October 7, 2025, Envoy Medical entered into a Securities Purchase Agreement to issue and sell 3,007,524 shares of Class A common stock at $1.33 per share, raising approximately $4 million in a registered direct offering. Concurrently, the company issued warrants to purchase up to 9,022,572 shares, potentially generating an additional $12 million if fully exercised. The proceeds are intended for working capital and general corporate purposes, with H.C. Wainwright & Co. acting as the exclusive placement agent.
The most recent analyst rating on (COCH) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Envoy Medical stock, see the COCH Stock Forecast page.
On October 7, 2025, Envoy Medical announced that it received FDA approval to advance its pivotal clinical trial for the Acclaim® cochlear implant to the final stage, following promising three-month data from the initial participants. This approval allows the company to expedite its timeline by three to six months and reduce its capital needs by $10-$15 million, positioning Envoy Medical to potentially redefine the cochlear implant market by addressing the needs of a largely untapped market of U.S. adults who prefer fully implanted devices over traditional external hardware.
The most recent analyst rating on (COCH) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Envoy Medical stock, see the COCH Stock Forecast page.